Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.
Actively Recruiting
Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of macupatide and eloralintide, alone or combined, in managing weight among adults who are overweight or obese but do not have type 2 diabetes. The study is conducted under a master protocol and seeks to understand how these treatments affect body weight changes over time. Participants are randomly assigned to one of several groups to receive macupatide, eloralintide, their combination, or a placebo. All treatments are given through subcutaneous injections. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The main treatment period lasts about 36 weeks, with additional assessments extending to around 64 weeks. During the study, participants will be closely monitored through various visits to assess changes in body weight and body mass index. Researchers will measure the percentage change in body weight from the start of the study to week 36 and beyond. Safety and adherence will also be tracked throughout the study, which lasts approximately 64 weeks in total.
Actively Recruiting
Researchers are conducting a Phase 3b4 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of once daily subcutaneous injections of elamipretide in male patients aged 5 to 55 years with genetically confirmed Barth syndrome BTHS. The study aims to confirm the efficacy of elamipretide, already approved in the United States as FORZINITY based on improved knee extensor muscle strength, an intermediate clinical endpoint. Participants will receive once daily subcutaneous injections of either elamipretide or a matching placebo for 72 weeks. The elamipretide is provided as a sterile aqueous solution in multi-dose glass vials. The trial includes two parallel groups undergoing this treatment regimen under quadruple masking to compare outcomes between the active drug and placebo over the study period. During the study, participants will be monitored regularly with assessments including efficacy and safety evaluations at baseline and throughout the 72-week treatment period. Researchers will measure primary and multiple secondary efficacy endpoints related to muscle strength and function. Safety monitoring and adherence to study requirements will be ensured, with participation lasting for the full 72 weeks of treatment exposure.
Actively Recruiting
Researchers are studying the long-term effects of aleniglipron, taken once daily, in adults with obesity or overweight who also have weight-related health problems. This Phase 3 global, randomized, placebo-controlled, and double-blind trial aims to evaluate how well aleniglipron works, how safe it is, and how well patients tolerate it over at least 76 weeks. The study also compares aleniglipron with placebo in terms of body weight changes, blood pressure, lipid levels, and patient-reported outcomes. Participants will be randomly assigned to receive one of three doses of aleniglipron or a placebo, all taken orally once daily. Along with the medication, all participants will follow a reduced-calorie diet and increase physical activity. The treatment phase lasts at least 76 weeks, during which effects on weight and other health measures will be assessed. During the study, participants will undergo assessments of body weight, waist size, blood pressure, cholesterol, blood sugar, and quality of life measures from the start through week 76. Researchers will monitor safety and tolerability throughout the treatment period. This long-term study will help understand the impact of aleniglipron on weight management and related health factors over more than a year of treatment.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Healthy Volunteer
Researchers are building on previous studies involving over 2,000 people to improve machine learning models that predict how individuals respond to different foods. The goal is to advance precision nutrition science and provide personalized dietary advice. This study uses both controlled dietary tests and free-living periods to observe responses to various meals and factors like exercise, sleep, and time of day. It also incorporates a commercial product to reach many participants who collect data through digital and biochemical devices. Participants will take part for 6 to 14 days. On the first day, they will wear a continuous glucose monitor on their arm. They will then eat two standardized meals each day, provided by the study team, and track their food intake using a digital app. After this period, participants can eat freely but must continue logging all meals, snacks, drinks, sleep, physical activity, mood, hunger, and medication use on the app. The study includes use of wearable devices and collection of blood and stool samples among users of the commercial product. Participants will complete questionnaires about their diet, lifestyle, and psychological state before and during the study. Continuous glucose levels will be monitored every 5 minutes during the intervention. Regular contact via phone, app, and messages will support compliance. Some participants may join a follow-up study to try dietary advice from the app for up to a year, reporting weight, bowel habits, hunger, energy, and app usage. The study measures glucose, gut microbiome diversity, blood lipids, hunger, and other health indicators throughout the study period.
Actively Recruiting
Researchers are conducting a cluster randomized clinical trial to evaluate a multi-level intervention involving shared decision making training for breast surgeons and a patient decision aid for women aged 70 and older with low-risk Stage I breast cancer. This study aims to improve treatment decisions and outcomes by supporting communication between surgeons and older women facing breast cancer treatment choices. The trial is being conducted across seven large health systems in the U.S. The intervention includes a one-hour shared decision making training for surgeons and providing eligible patients with a tailored decision aid before their first surgical visit. Surgeons randomized to the intervention arm receive training via live televideo or video recording and ongoing support including access to decision tools and feedback on challenging cases. Patients receive the decision aid by mail, email, or patient portal. Surgeons in the usual care arm continue their standard treatment discussions without additional support. The study plans to recruit 44 surgeons and over 1,100 women over three years. Participants will be observed through medical record reviews to determine treatments received and outcomes such as breast cancer recurrence and survival over 6 months to 3.5 years. Patients and caregivers will complete surveys at one week and six months after the initial surgical visit to report on shared decision making quality, knowledge, decisional conflict, quality of life, and treatment satisfaction. Surgeons will complete baseline and end-of-study surveys, with some participating in interviews to provide feedback. The study will also assess healthcare costs and the feasibility of implementing the intervention in clinical practice.
Actively Recruiting
This research aims to evaluate how the prosthetic replacement of the ocular surface ecosystem PROSE treatment may affect mental health, focusing on mood disorders like depression. It explores the connection between changes in mental health and improvements in eye symptoms or vision. PROSE is used for certain eye surface diseases, including dry eye and ocular Graft versus Host Disease, which are linked to mental health challenges due to pain and vision loss risks. PROSE treatment involves customizing a rigid gas permeable scleral lens that protects and lubricates the eye by filling it daily with preservative-free saline. This treatment is designed to reduce eye pain, prevent damage, and improve vision. The study follows patients considering PROSE or scleral lenses for their eye conditions, assessing their mental health and eye symptoms over time. Participants will be assessed using questionnaires measuring depression PHQ-9, eye symptom severity Ocular Surface Disease Index, and quality of life Visual Function Questionnaire 25 at enrollment and at 28 and 84 days after receiving PROSE treatment. The study collects data to understand how eye treatment might relate to changes in mood and daily functioning over six months.